Please login to the form below

Not currently logged in
Email:
Password:

New Molecular Entities

This page shows the latest New Molecular Entities news and features for those working in and with pharma, biotech and healthcare.

EMA sees approval numbers rise in 2018

EMA sees approval numbers rise in 2018

The figures nevertheless show the EMA is still lagging significantly behind the FDA, the US drug regulator reaching a record-breaking tally of 59 new molecular entities for the year. ... Lastly, the EMA’s key human medicines committee, the CHMP, has a

Latest news

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    The final tally for novel drug approved at the US regulator last year stands at 59 new molecular entities as of 27 December – smashing all previous records. ... The FDA approved 46 drugs in 2017, which had itself matched a 2015 record, but last year

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    Barron made much of GSK’s immunology and immuno-oncology portfolio on the company’s interim results call, saying it has 27 new molecular entities (NMEs) in these areas which account ... Meanwhile, vaccines grew 12% to £1.92bn led by new shingles

  • GSK: we won’t be splitting up any time soon GSK: we won’t be splitting up any time soon

    The company has 27 immunomodulatory new molecular entities (NME) in clinical trials, around 60% of its total clinical pipeline. ... Also announced was a major new alliance with consumer gene testing company 23andMe.

  • Pharma is ‘getting lower returns on R&D’ Pharma is ‘getting lower returns on R&D’

    Deloitte also welcomes an increase in the number of approvals of new molecular entities, orphan drugs and break/fast-tracked therapies which its says “leads us to present an overall optimistic ... with new ways of engaging patients in clinical trials

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    Sanofi said in a preview of the event this morning that its pipeline currently has 71 projects, including 37 new molecular entities and novel vaccines, with nine potential marketing applications in

More from news
Approximately 2 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    In one fell swoop three new giant specialists will emerge: Novartis claims the cancer crown; GSK vaccines; Lilly Animal Health. ... Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    Despite the new schemes, healthcare in China is still considered expensive, with out-ofpocket payments commonly high. ... Conversely, however, Brazil's uptake of New Molecular Entities (NMEs) between 2006-2010 was the highest of the BRIC nations – with

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Chancellor Merkel has proposed a new system of financial regulation within the EU. ... Source: EFPIA, 2009. According to Vfa in 2010 only 26 new molecular entities were launched in the German market, compared to 36 in 2009.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics